ALMS
Alumis Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$11.16
−1.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 7.4M | 24.1M | — | — | — |
| Cost of Revenue | 871.0K | 3.5M | 3.2M | — | 250.0K |
| Gross Profit | 6.5M | 20.6M | (3.2M) | — | (250.0K) |
| Operating Expenses | |||||
| R&D Expense | 346.6M | 386.0M | 265.6M | 137.7M | 101.1M |
| SG&A Expense | 77.1M | 91.9M | 35.2M | 20.5M | 12.5M |
| General & Admin Expense | 77.1M | 91.9M | 35.2M | 20.5M | 12.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 41.8M | (30.1M) | (3.2M) | — | — |
| Total Operating Expenses | 465.5M | 447.8M | 297.6M | 158.2M | 113.6M |
| Cost and Expenses | 466.4M | 451.3M | 300.8M | 158.2M | 113.8M |
| Operating Income (EBIT) | (459.0M) | (427.2M) | (300.8M) | (158.2M) | (113.8M) |
| Non-Operating | |||||
| Interest Income | 18.4M | 14.2M | 12.0M | 3.4M | 2.0M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 18.4M | 14.2M | 12.0M | 3.4M | 2.0M |
| Other Non-Op Income/Expense | 18.3M | 175.3M | 6.5M | 3.2M | 1.9M |
| Non-Operating Income (excl Interest) | (13.5M) | (175.3M) | (6.5M) | (3.2M) | (1.9M) |
| EBT (Pre-Tax Income) | (440.7M) | (251.9M) | (294.2M) | (155.0M) | (111.9M) |
| Income Tax Expense | (1.8M) | (8.6M) | — | — | — |
| Bottom Line | |||||
| Net Income | (439.0M) | (243.3M) | (294.2M) | (155.0M) | (111.9M) |
| Earnings from Cont. Ops | (439.0M) | (243.3M) | (294.2M) | (155.0M) | (111.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (439.0M) | (243.3M) | (294.2M) | (155.0M) | (111.9M) |
| Per Share | |||||
| Basic EPS | ($3.80) | ($2.32) | ($10.38) | ($2.99) | ($14.93) |
| Diluted EPS | ($3.80) | ($2.32) | ($10.38) | ($2.99) | ($14.93) |
| Revenue Per Share | $0.06 | $0.03 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 127.7M | 850.3M | 28.3M | 51.8M | 7.5M |
| Diluted Shares Outstanding | 127.7M | 850.3M | 28.3M | 51.8M | 7.5M |
| Profitability Metrics | |||||
| EBITDA | (442.9M) | (248.4M) | (291.1M) | (153.7M) | (111.7M) |
| D&A | 2.7M | 3.5M | 3.2M | 1.3M | 250.0K |
| EBIT | (445.5M) | (251.9M) | (294.2M) | (155.0M) | (111.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026